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proper diagnosis and to administer subsequent optimum
treatment. Throughout the centuries, many attempts were
made to control this ever-challenging problem, especially
in this century mostly led by surgeon,3 but the results of
the surgical treatment were often a disasterous failure
mainly because of poorly planned and overaggressive sur-
gical treatment on the basis of limited knowledge of the
complex nature of vascular malformation lesions.4
Recently, a multidisciplinary approach was introduced as
an advanced system with maximum efficiency to handle
complicated diseases such as vascular malformation, which
requires close interdepartmental coordination for the
proper management.5-7 We adopted this new concept for
the orchestrated effort of maximum coordination among
various related specialists, and the CVM Clinic was orga-
nized as a referral center at Samsung Medical Center and
Sungkyunkwan University, Seoul, South Korea, in
February 1996, with the 15 following departments
involved: vascular surgery, pediatric surgery, orthopedic
surgery, plastic surgery, pediatrics, anesthesiology, inter-
ventional radiology, general radiology, general medicine,
cardiovascular medicine, physical medicine and rehabilita-
Congenital vascular malformation (CVM) has been
known as one of the most difficult diagnostic and thera-
peutic enigmas in the practice of medicine. The clinical
presentations are extremely variable, ranging from an
asymptomatic birthmark to a life-threatening condition.
These extremely variable findings that patients present
have been a major challenge even to the most experienced
clinicians.1,2 Compounding these challenging conditions
is the extreme rarity of the congenital vascular lesions,
which makes it difficult to gain a learning curve to make a
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Background: Complex forms of congenital venous malformation have defied proper classification and confounded ther-
apy. Through a newly designed multidisciplinary approach, these venous defects were properly diagnosed and classified
according to the Hamburg classification. Absolute ethanol was adopted as a new scleroagent for this complex form of
venous defects to improve overall treatment results with acceptable morbidity and recurrence rates. 
Patients and Methods: Among 318 patients aged 2 months to 60 years (130 men: mean age, 24.6 years; 188 women:
mean age, 24.5 years), 143 patients were confirmed as having venous defects predominantly (45%). We conducted diag-
nostic evaluation with magnetic resonance imaging, whole body blood pool scan, duplex scans, transarterial microal-
bumin lung scans, air plethysmography, bone x-ray film, and angiography. Thirty of 143 patients were indicated for
the absolute ethanol sclerotherapy for the complex form of venous defects, and they completed 98 sessions of multi-
stage therapy with direct puncture technique. Follow-up assessment (minimum, 6 months; average, 10.2 months) was
made as early results after completion of therapy.
Results: The immediate success rate at the completion of treatment through 98 sessions on 30 patients was 92% (90/98).
The reason for the failure of 8% (8/98 sessions) was mainly due to the lesion’s inaccessibility to the nidus to deliver the
alcohol safely. On follow-up assessment available on 28 of 30 patients, overall improvement of the lesions with good to
fair response on clinical assessment was obtained in 27 (96%) of 28 patients. Similar good to fair responses were obtained
on whole body blood pool scan assessment (14 [93%] of 15 patients) and also on magnetic resonance imaging assess-
ment (12 [93%] of 13 patients). Various major to minor acute complications developed during the procedure in eight
(26.7%) of 30 patients through 16 (16.3%) of 98 sessions of the therapy: ischemic bullae, tissue fibrosis, deep venous
thrombosis, pulmonary embolism, peripheral nerve palsy, and temporary pulmonary hypertension. All 24 incidences of
complication were successfully managed with full recovery except one case of permanent peroneal nerve palsy that was
present during 18 months of follow-up. No single recurrence has been detected to date.
Conclusion: Absolute ethanol sclerotherapy alone can deliver excellent results in complex forms of venous malforma-
tions with considerable but acceptable morbidity and may be able to reduce the morbidity involved with the conven-
tional surgical therapy alone on complex forms of venous malformation. No recurrence or deterioration of the therapy
results was observed during the follow-up period (average, 10.2 months) after the completion of multistaged therapy.
(J Vasc Surg 2001;33:764-72.)
tion, dermatology, psychiatry, nuclear medicine, and social
services.8 We also adopted a modified version of the
Hamburg classification.5-9 Malformation is first classified
by the predominant component of vascular defect (eg,
arterial, venous, arteriovenous [AV] shunting, combined
or lymphatic); then, it is further classified to truncular or
extratruncular form depending on the embryonal stage
when developmental arrest occurred and remained
through (Table I).5,9
The 1988 Hamburg classification has excellent clinical
applicability with minimum confusion because the termi-
nology itself provides substantial information of anato-
mopathophysiologic status of vascular malformation on
the basis of embryologic development.5,6,8 Because of the
pathognomic characteristics of vascular defects that origi-
nated from mesenchymal cells, defect at the earlier stage of
organogenesis especially has been known for its notorious
reputation of recurrence, aggravation, or both by minimal
stimulation or change of milieu.10 Therefore, with the evi-
dence of no recurrence and acceptable morbidity, absolute
ethanol was selected as the major scleroagent at our clinic
and carefully tried on our patients with venous malforma-
tion after the detailed instruction by Yakes and Parker.11
MATERIALS AND METHODS 
A total of 318 patients aged between 2 months and 60
years (130 men: mean age, 24.6 years; 188 women: mean
age, 24.5 years), presenting with various symptoms and
signs related to the vascular anomaly, were thoroughly
evaluated per protocol6 of the clinic (April 1996 through
September 1998) and properly classified according to the
new Hamburg classification,5 which is a modified form of
the original Hamburg consensus of 1988, enabling the
proper use of a newly designed computer software sys-
tem12 for the advanced CVM management.
The initial evaluation of all patients with CVM
includes a careful physical examination, the recording of
each patient’s history, and a basic laboratory evaluation
with various combinations of noninvasive to less-invasive
tests depending on indications: bone x-ray study of bone
length and pelvis tilt for the assessment of growth discrep-
ancy; arterial Doppler study including waveform analysis;
arterial photoplethysmography; venous duplex scan of
color Doppler imaging and spectral analysis; aeroplethys-
mography; strain-gauge plethysmography; volumetry;
transarterial radioisotope study with labeled microsphere
albumin for lung scan known as transarterial lung perfu-
sion scan; transvenous radioisotope study with labeled red
blood cells known as whole body blood pool scan
(WBBPS); magnetic resonance imaging (MRI); and
radioisotope lymphoscintigraphy.2,8 However, arterial
Doppler study and arterial photoplethysmography are sel-
dom indicated except for the venous malformation com-
bined with micro-AV shunting component (eg, Parkes
Weber syndrome). Also, strain-gauge plethysmography
and volumetry are seldom indicated except for a
hemolymphatic combined form of vascular malformation
(eg, Klippel-Trénaunay syndrome). Invasive study, usually
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reserved until required for the treatment or for the differ-
ential diagnosis, includes various kinds of venography of
ascending, descending, or regional (segmental) type; per-
cutaneous direct puncture angiography; and standard,
selective, or superselective arteriography. 
A total of 143 of the 318 patients were confirmed to
have predominantly venous defects (Table II). On the
basis of the consensus through joint review by the clinic
team, 30 of 143 patients were selected for the absolute
ethanol multistaged sclerotherapy alone because of the
following criteria: (1) lesions with symptoms and signs
(eg, pain, discomfort, heavy sensation, difficult mobility
and difficult motion of joint; swelling, limited range of
motion; ulcer, hemorrhage, lymph leak, stasis dermatitis,
port-wine stains; functional impairment and cosmetically
severe deformity); (2) lesions located at trauma-prone
region with potential risk of complication (eg, hemarthro-
sis)—knee, ankle, foot, elbow, wrist and hand; (3) lesions
located at a potentially life-threatening vital area that com-
promises seeing, hearing, eating, or breathing (eg, prox-
imity to airway); and (4) combined abnormal bone
growth with limb length discrepancy due to vascular bone
syndrome.13,14 Most of the patients (28 of 30) indicated
for sclerotherapy have at least two if not three conditions
to meet these criteria for the treatment. These 30 patients
underwent 98 sessions with independent ethanol scle-
Table I. Classification of congenital vascular malforma-
tion: Hamburg classification 1988 with modification5,9
Species Anatomical forms
Predominantly arterial defects Truncular forms
Aplasia or obstruction
Dilatation
Extratruncular forms
Infiltrating
Limited
Predominantly venous defects Truncular forms
Aplasia or obstruction
Dilatation
Extratruncular forms
Infiltrating
Limited
AV shunting defects Truncular forms
Deep AV fistula
Superficial AV fistula
Extratruncular forms
Infiltrating
Limited
Combined vascular defects Truncular forms
Arterial and venous
Hemolymphatic
Extratruncular forms
Infiltrating hemolymphatic
Limited hemolymphatic
Predominantly lymphatic Truncular forms
defects Aplasia or obstruction
Dilatation
Extratruncular forms
Infiltrating
Limited
rotherapy, which is indicated, in general, for the lesion that
will require the treatment, but the lesion is located at a
surgically inaccessible or difficult area and more morbidity
is anticipated with surgical therapy. For example, when the
lesion that needs therapy is located beyond the deep fascia
with extensive involvement of muscle, tendon, and bone,
or is extended into retroperitoneal, pelvic, and gluteal
regions from the extremity, ethanol sclerotherapy is 
the treatment of choice to minimize or avoid surgical
treatment-related morbidity. Among the many available
sclerosing agents for the sclerotherapy of venous malfor-
mation, absolute ethanol was selected as the major scler-
osing agent for our patients because absolute ethanol was
shown to induce permanent obliteration of vessel lumen
with the least chance of recanalization because it denatures
blood protein, dehydrating vascular endothelial cells, pre-
cipitating their protoplasm, denuding the vascular wall of
endothelial cells, and segmentally fracturing the vessel wall
so that total tissue devitalization demonstrates its curative
potential with permanent thrombosis, in contrast to other
embolic agents that only provide palliation through tem-
porary effect with a high recurrence rate.15-18
The evaluation of the treatment result of each of the 98
sessions of multistaged ethanol sclerotherapy was made
through periodical interim assessment by a clinic team
together mainly to confirm or change the initial treatment
strategy, until the completion of planned therapy. Among
the 30 patients who completed 98 sessions of sclerother-
apy, 28 patients, who were confirmed for the successful
delivery of ethanol into the lesion with angiography on
each session, were available for all proper follow-up by clin-
ical assessment. Assessment with WBBPS and MRI was also
done to compare with the results of clinical assessment. 
RESULTS
Nearly two thirds of the 143 patients with venous mal-
formation at our clinic are female (84/143). Most, 91 of
143, are aged between 0 and 20 years. The predilection
site of this venous malformation is the lower extremity in
the near majority (68/143), followed by the head and
neck region (30/143), and a significant number of the
patients have the lesion on multiple sites (eg, trunk and
limb) (Table III). 
The immediate success rate of the sclerotherapy in 98
sessions for 30 patients was 92% (90/98) with failure in 8%
(8/98). Of eight failed sessions, seven failed because of the
lesion’s inaccessibility, due to a lack of proper veins for direct
puncture technique, to the nidus to deliver the scleroagent,
and one failed session was the premature interruption of the
therapy due to the fear of extension of the thrombus by the
scleroagent from the malformed vein to the normal deep
vein, which are directly connected to each other.
A total of 28 of 30 patients were available for follow-up
assessment (minimum, 6 months; average, 10.2 months)
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Table II. Demographic data of classification* of congen-
ital vascular malformation† 
No. of
Type patients Total no. (%)
Predominantly AV shunting defects 31 (10)
Truncular
Deep AV fistulas 2
Extratruncular
Infiltrating 28
Limited 1
Predominantly venous defects 143 (45)
Truncular
Aplasia or obstruction 2
Dilatation 3
Extratruncular
Infiltrating 112
Limited 26
Combined vascular defects 16 (5)
Extratruncular
Infiltrating hemolymphatic 14
Limited hemolymphatic 2
Predominantly lymphatic defects 99 (31)
Truncular
Aplasia or obstruction 86
Dilatation 3
Hypoplasia 3
Extratruncular
Infiltrating 1
Limited 6
Unclassified‡ 29 (9)
*Based on Hamburg Classification (1988).
†Patients with CVM registered at CVM Clinic, Vascular Center, Samsung
Medical Center, Seoul, South Korea (April 1996 through September
1998). A total of 318 cases.
‡Mostly venous defects, clinically.
Table III. Demographic data of venous malformation*
Parameter No. of patients
Sex
Female 84
Male 59
Total: 143
Mean age
Male: 16.9 y
Female: 19.6 y
Total: 18.5 y
Age range (y)
0-10 57
11-20 34
21-30 25
31-40 12
41-50 11
51-60 4
Total: 143
Location of lesions
Multiple 17
Lower extremity 68
Trunk 12
Upper extremity 16
Head & neck 30
Total: 143
*A total of 143 patients with venous malformation among 318 patients
registered at CVM Clinic, Samsung Medical Center (April 1996 through
September 1998).
after the completion of 90 sessions of successful multistaged
therapy (Table IV). On clinical assessment, 27 of 28
patients, confirmed for the successful delivery of ethanol to
the nidus of the lesion through angiographic evaluation,
have shown overall clinical improvement with fair to good
response (96%). Clinical assessment is based on subjective
improvement of clinical symptoms after the completion of
multisession therapy. Each symptom and sign (eg, pain, dis-
comfort, ache, stiffness, limited motion of joint or gait) the
patient had before starting the treatment was properly doc-
umented through the description by the patient or family
members, including medical photographs. This subjective
improvement of symptoms was further assessed simultane-
ously with objective evidence of the improved clinical signs,
including reduction of the size of lesion or general swelling
or improved range of motion of the joint. Of 28 clinically
assessed patients, 15 were also available for WBBPS assess-
ment, which revealed an equivalent finding of good to fair
clinical response in 93% (14/15). 
WBBPS assessment of the treatment results were
based on quantitative measurement of the reduction of the
radioisotope count over the designated lesion (region of
interest) after the treatment. On serial tests, a reduction of
50% or more was interpreted as “good,” and a reduction
of 30% to 50% was “fair.”
MRI assessment was available on 13 patients after
completion of therapy. It has also shown good to fair
responses in 93% (12/13), which are compatible to the
clinical and WBBPS findings.
MRI findings read by three independent specialists
were interpreted as “good” for definitely improved lesion
after therapy, as declared by all three radiologists, and as
“fair” for the borderline improvement or discrepancy
among the three radiologists’ opinion. One patient with
poor response on clinical assessment has shown the same
poor response on WBBPS assessment, and it was suspected
to be due to the aggravation of a possibly combined com-
ponent of capillary malformation after the third successful
sclerotherapy. One patient’s poor response on MRI assess-
ment is due to the aggravation of the nontreatment site
(Table IV). Of the 98 sessions of sclerotherapy in 30
patients, 16 sessions (16.3% per session) in 8 patients
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(26.7% per patient) were complicated with 24 various
minor to major acute complications, including superficial
ischemic bullae (9), tissue fibrosis (2), tissue necrosis (2),
deep vein thrombosis of lower extremity (1), pulmonary
embolism (1), nerve palsy (temporary and permanent)
(5), and transient pulmonary arterial pressure elevation
during the procedure (4)(Table V). Of the five nerve
palsies, three facial nerve palsies and one peroneal nerve
palsy completely and spontaneously resolved within 2 to 6
months. However, one peroneal nerve palsy remained
without resolution for 18 months on follow-up and is sus-
pected to be permanent without evidence of improvement
on various tests. However, all other 23 complications were
completely resolved eventually, and there has been no CVM
recurrence seen among 30 patients beyond the follow-up
period (6-20 months; average, 10.2 months) of multi-
staged therapy to date.
DISCUSSION
CVM is a result of the arrest of normal vascular devel-
opment during the organogenesis and the failure of
orderly resorption of the embryologic primitive vascular
elements with subsequent persistence of immature vascu-
lar structures that should have disappeared at birth but
remain as anomalies.10,19 Therefore, depending on the
stage of embryologic morphogenesis when the develop-
mental arrest should occur, various types of vascular mal-
formations may remain, even in combination. Its clinical
manifestation will be extremely variable, depending on the
degree of soft tissue, muscle, and osseous involvement and
may also stay dormant for years. All vascular malforma-
tions exist at birth because they are congenital lesions,
rather than newly developed vascular tumors after birth,
known as hemangiomas, which are essential for the proper
differential diagnosis. 
Noninvasive tests are usually sufficient for the diagno-
sis of CVM per se, especially for predominantly venous
defects. For them, invasive tests can be reserved as the final
diagnostic tool for the therapeutic purpose as a road map,
in general.2 Diagnostic procedures, therefore, are generally
Table V. The early and late complications of absolute
ethanol sclerotherapy*
Complication No.
Temporary PAP elevation 4
Nerve palsy 5†
Pulmonary embolism 1
Ischemic bullae 9
Tissue necrosis 2
Deep vein thrombosis 1
Tissue fibrosis 2
24 (Total)
*Minor to major complication through 16 sessions in 8 patients with
venous malformation subjected to 98-multisession sclerotherapy.
†Three facial nerve palsies and two peroneal nerve palsies.
PAP, Pulmonary arterial pressure.
Table IV. Follow-up results* of multistaged absolute
ethanol sclerotherapy
Assessment AXR & Sx† WBBPS MRI
Good 25 (89%) 11 (73%) 11 (85%)
Fair 2 (7%) 3 (20%) 1 (8%)
Poor 1 (4%)‡ 1 (7%)‡ 1 (8%)§
Total available 28 15 13
*Follow-up for minimum 6 months (average, 10.2 months) on 28 cases.
†Clinical assessment of angiographically successful therapy.
‡Due to possible iatrogenic aggravation after the third sclerotherapy.
§Aggravation of nontreatment site.
AXR, Angiography; MRI, magnetic resonance imaging; Sx, symptoms;
WBBPS, whole body blood pool scan.
limited to these minimum noninvasive tests if possible,
especially for the pediatric age group younger than 2 years
with venous malformation unless early or immediate inter-
vention is indicated for various reasons (eg, rapid bone
growth discrepancy in lower extremity; lesions located at
potentially life-threatening vital areas to compromise see-
ing, hearing, eating, or breathing). Also, invasive study is
deferred until needed.2,6 However, more extensive invasive
study might be needed from the beginning without age
limit to make precise differential diagnosis to rule out other
combined components of vascular defects, especially AV
shunting defects. AV shunting defects reflect the strong
potential of residual mesenchymal cells evolving in mal-
formed embryonal tissue so that extreme care will be
required not to overlook and provoke its stimulation and
to let it erupt like a volcano, in contrast to the venous
defects. The final diagnosis of venous malformation should
also aim at the proper assessment of the severity, location,
and the extent of the involvement to surrounding struc-
tures. At the same time, the baseline study should include
a careful search throughout the body for other possible
combined vascular malformation elsewhere besides clini-
cally obvious malformation lesion. For the routine follow-
up assessment of the immediate, interval, and long-term
treatment results, various noninvasive tests (WBBPS,
duplex scan, and transarterial lung scan) can provide suffi-
cient information alone or together. Furthermore, when
MRI is added to these tests, the overall value as the assess-
ment parameter is close to those of angiography, which is
still the gold standard. Angiography, therefore, is seldom
needed only for the follow-up assessment. Recently intro-
duced WBBPS to the arena of CVM, previously known as
multigated acquisition scan for cardiac evaluation, provides
excellent information not only as a screening test to look
for hidden CVM elsewhere, but also as a follow-up test,
especially during the interim period of multistaged therapy
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Fig 1. Management of predominantly venous malformation with
alcohol sclerotherapy. A, Clinical appearance of protruding lesion
over left cheek with symptoms. B, MRI finding of infiltrating
extratruncular type of venous defects along left masseter muscles
(arrowhead). C, Pretreatment baseline assessment of lesion with
WBBPS (arrowhead).
through the quantitative measurement of the reduction 
of the lesion by the counting of scintigraphic activity of
technetium-tagged erythrocyte at the lesion.
Complete extirpation of the complex form of venous
defect is still extremely difficult if not rarely possible.
Furthermore, the treatment of venous defects is not rou-
tinely indicated in contrast to AV shunting defects, unless
the lesion meets the criteria for the indication of treatment
as mentioned in detail in the “Materials and Methods” sec-
tion. Even if the treatment is indicated, the benefit and loss
by the morbidity after the treatment should be weighed
properly, regardless of the treatment modality. The role of
JOURNAL OF VASCULAR SURGERY
Volume 33, Number 4 Lee et al 769
sclerotherapy has been increased in the management of
vascular anomalies in general, and its role has been slowly
expanded to replace a significant part of the traditional role
of surgical therapy, especially for the venous lesions that are
surgically difficult or at inaccessible areas (Figs 1 and
2).20,21 As long as it is the predominantly venous defects,
the attitude to the treatment would be safer on the con-
servative side against traditional aggressive approach.
When the thorough assessment declares the lesion as a dif-
fuse infiltrating type of extratruncular form of venous
defect, involving multiple structures, the priority of the
treatment modality should be given to the sclerotherapy
Fig 1, contd. D, Venographic finding of malformed vein lesion through direct puncture technique. E, Venographic finding of imme-
diate success of sclerotherapy by alcohol injection into nidus of lesion. F, Follow-up WBBPS finding (arrowhead) of treatment results
(after three sets of sclerotherapy).
D E
F
venous defect together, the lesion of the extratruncular
form would be safer to control first with sclerotherapy, if
possible, before starting the proper surgical treatment of
the truncular form of defect. If the patient also has a com-
bined lesion of AV shunting component, the AV shunting
lesion has to be treated immediately with all the available
surgical and nonsurgical methods as soon as and also as
much as possible before any consideration of the treatment
for venous defect, because AV shunting defects will con-
tinue to grow and eventually become the potential limb or
a life-threatening condition such as cancer.
There are large varieties of embolosclerosing agents
(vaso-occlusive substances) for the management of various
CVMs to produce endovascular obliteration,22 but there is
no “ideal” vaso-occlusive substance to satisfy all the indi-
cations.23 Absolute ethanol has been reported to be the
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first, once the treatment is indicated, as illustrated above in
detail. However, a limited (localized) form of extratruncu-
lar type of venous defects may be handled much more
effectively with conventional surgical excision technique
with minimum morbidity as before than with the costly
multistaged sclerotherapy, because each session of multi-
staged ethanol sclerotherapy has to be carried out with 
the patient under general anesthesia, and a careful high-
technique monitoring of cardiovascular status intraopera-
tively and the patient has to be observed carefully for 24 to
48 hours under the admission status. A truncular form of
venous defect, instead, should be handled with various
kinds of traditional nonhemodynamic or hemodynamic
surgery (eg, venous bypass graft, repair or excision of
venous aneurysm, staged excision of embryonal or mar-
ginal veins). When the patient has different forms of
B
C
Fig 2. Management of predominantly venous malformation with
alcohol sclerotherapy. A, Clinical appearance of extensive lesion
affecting tongue, cheek, lips, and perioral region with severe dis-
ability. B and C, MRI finding of extensive nature of diffuse infil-
trating extratruncular type of venous defects.
most reliable substance to occlude thin peripheral artery
and vein, although there is significant risk of major adverse
effects (eg, skin necrosis, nerve damage).22 In our limited
clinical experiences with this absolute ethanol (follow-up
average, 10.2 months; minimal, 6 months after the com-
pletion of therapy), excellent results of complete and per-
manent vaso-occlusion were obtained with no recurrence,
so far, with the prospect of a “cure” in selected cases, espe-
cially in this kind of “low-flow” venous malformation,
although the results are somewhat variable on “high-flow”
lesions like AV shunting malformation. However, multiple
sessions are required so that a small dose of ethanol can be
given at each session to reduce the risk of major morbid-
ity by this extremely powerful absolute ethanol injection.
Also, high-technology monitoring and high-technology
imaging are required in addition to general anesthesia dur-
ing the procedure. These complicated procedures to
deliver absolute ethanol safely only make this sclerother-
apy expensive as routine practical use for the management
of overall venous defects, although the results are, in gen-
eral, excellent with a good prospect of long-term results of
no recurrence.
We prefer to wait at least 2 to 3 weeks between the
multistaged sclerotherapy to let the patients recover from
the previous therapy. Furthermore, it allows the local tis-
sue reaction to be subsided.24
It must be emphasized that sclerotherapy is not a cura-
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tive but palliative treatment in general, especially for most
complex and dynamic lesions involving not only the vas-
cular system but also any system by infringing on almost
any structure and function of the affected area.3
Treatment is sometimes indicated even prophylactically in
those circumstances showing a tendency toward signifi-
cant decompensation. Intervention for early chronic
venous insufficiency caused by this inborn defect and sec-
ondary decompensation of the collecting veins may also
justify the prophylactic therapy, reducing the volume and
pressure effect. This kind of aggressive approach with scle-
rotherapy alone or in conjunction with surgery helps to
moderate the clinical symptoms to a substantial degree,
especially for venous malformation, so that subsequent
conservative therapy becomes more effective and success-
ful. Thus, the new concept of an integrated complex treat-
ment program that is based on ablative or reconstructive
vascular surgery, percutaneous transvenous sclerotherapy,
general supported measurement, physical and mental
rehabilitation, and social service should become the base
of total care management of the venous malformation
through the multidisciplinary approach for multimodality
treatment as one team.8
New establishment of the referral system to a multi-
disciplinary clinic like ours has given us a unique opportu-
nity of fast accumulation of the advanced knowledge and
experiences besides better understanding of the anato-
Fig 2, contd. D, Venographic finding of successful management
of malformed vein with alcohol injection into nidus through
direct puncture technique. E, Excellent results of multistage alco-
hol sclerotherapy (8 sessions) showing dramatic reduction of
lesion enough to close mouth.
D
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mopathophysiological characteristics of various type of
CVM and allowed us to evaluate the new role of scle-
rotherapy with absolute ethanol to venous malforma-
tion.25,26 According to our experiences, this new modality
of sclerotherapy with improved technology has opened a
new frontier especially for the management of venous mal-
formation though there is still controversy over the
expanded role of absolute ethanol as a new sclerosing
agent. However, we think the current issue on this new
strategy for CVM management is how to assess the rela-
tive roles of surgery and vaso-occlusive angiotherapy
(embolosclerotherapy) on various malformations and how
they can best be combined to produce the optimal results. 
CONCLUSION
Sclerotherapy with absolute ethanol can become an
important new modality of therapy for venous malforma-
tion, providing reasonable safety and relatively long-
lasting therapeutic results. Absolute ethanol sclerotherapy
can deliver excellent early results with no recurrence dur-
ing the limited follow-up (minimum, 6 months; average,
10.2 months) after the completion of multistaged therapy.
The risk of morbidity involved with the surgically oriented
traditional treatment strategy can be substantially reduced
by acceptance of the independent absolute ethanol scle-
rotherapy of direct puncture technique, especially on com-
plex forms of the infiltrating type of extratruncular venous
defect.
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